Amylx Pharmaceuticals Inc vs Medpace Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.86 (market cap $2.64B), while Medpace Holdings Inc trades at $602.96 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 6.4× Amylx Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMLX | MEDP | |
|---|---|---|
Market Cap | $2.64B | $16.90B |
Sector | Health | Technology |
52-Week High | $24.19 | $620.59 |
52-Week Low | $7.82 | $393.42 |
Enterprise Value | $2.39B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →